Non-opiate painkiller, AnestaGel, found superior in preclinical tests
AnestaGel uses a novel approach to delivering sustained-released analgesics into the target tissue via the Matrix, which is a tunable, biocompatible, and pH neutral platform.
InSitu Biologics has announced results from recent pre-clinical studies for its lead product, AnestaGel. AnestaGel is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.
In a series of independent tests performed under GLP regulations, comparing operative site injections of AnestaGel and Exparel from Pacira, AnestaGel was proven to last longer, and provide a greater analgesic effect than Exparel. In a separate test that determines the PharmacoKinetic(PK) effect for the painkiller bupivacaine, which is used in both AnestaGel and Exparel, bupivacaine was proven to be released from AnestaGel into the blood up to 96-120 hours after injection exceeding the presence of bupivacaine in the blood from both Exparel and straight bupivacaine injections.
"As we had hypothesized going in to these studies, we expected that AnestaGel would perform very well when compared to the non-opiate products available today," said Dr Jake Hutchins, Director of the Regional Anesthesia Acute Pain and Ambulatory Surgery division at the University of Minnesota, and the Pre-Clinical Study Director for InSitu Biologics. James Segermark, CEO of InSitu added: "Early on we believed that AnestaGel could be tuned to act as a short-term reservoir, essentially a non-pulsatile organ, and that is what we have now verified and validated. We look forward to the next steps that will bring this predictable, very long-acting, non-opiate product to patients that face the prospect of post-surgical pain." The company believes that AnestaGel could be used in three distinct markets for peri-operative pain management that represent nearly $31 billion in annual revenue in the US.
AnestaGel uses a novel approach to delivering sustained-released analgesics into the target tissue via the Matrix, which is a tunable, biocompatible, and pH neutral platform. This allows AnestaGel to provide target site-specific, non-migratory placement, a flexible and high dose drug-load reservoir capacity, and a tunable and predictable pharmacological effect.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.